We report a case of giant macular hole progression after rupture of giant retinal pigment epithelial detachment (PED). The patient was a 91-year-old man who had a giant PED in the left eye. He had bilateral hypermetropia (+2.00 dpt), and he had developed posterior vitreous detachment. The PED was 5,800 μm in diameter and 800 μm in height and ruptured during follow-up. A macular hole was formed, with a diameter of 400 μm, and the height of the PED had reduced to 360 μm. After 5 months, the macular hole expanded up to a diameter of 600 μm. Therefore, some cases of giant PED may lead to macular hole.
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Introduction
Pigment epithelial detachment (PED) may occur under various conditions, with or without neovascularization, usually associated with age-related macular degeneration. Although PED sometimes heals spontaneously, a large PED expands gradually in the majority of cases and may rupture, causing pigment epithelial defect within a few years [1] .
Idiopathic macular hole (MH) is caused by progression of vitreomacular traction from posterior vitreous detachment (PVD) due to aging when strong vitreous adherence to the fovea exists. Although cases of MH were originally reported in the setting of trauma, other causes or mechanisms such as retinal vitreous surgery or diabetic edema have been reported [2] [3] [4] [5] . Here, we present a novel MH formation that occurred after rupture of a giant PED.
Case Report
The patient was a 91-year-old man with a chief complaint of distorted vision in the left eye. On initial examination at Higashi Totsuka Denen Eye Clinic (by Y.T.), best-corrected visual acuity (BCVA) was 20/25 for oculus dexter (OD) and 20/50 for oculus sinister (OS); refractive error was +3.25/-2.50 × 100° (OD) and +4.50/-2.00 × 70°(OS), and intraocular pressure (IOP) was 12 mm Hg for both OD and OS. PVD had already developed in the left eye. Numerous drusen were present in both eyes. PED was noted, with a diameter of 5,800 μm and height of 800 μm in the left eye (Fig. 1a) . Ophthalmoscopy showed no findings suggestive of CNV such as subretinal hemorrhage, elevated gray or orange lesions, or a notch of PED. Optical coherence tomography revealed that there was no type 2 CNV, double-layer sign, or polypoidal lesion under the pigment epithelium. In addition, no CNV was observed during the clinical course.
After 3 months, he was referred to a second clinic because of worsening of symptoms and examined there (Totsuka Eye Clinic by H.T. and S.F.). At that time, BCVA was 20/20 OD and 20/125 OS, IOP was 12 mm Hg for OD and 11 mm Hg for OS; there was an MH and a PED, with the height reduced to 360 μm in his left eye (Fig. 1b) .
Considering his age and systemic condition, we did not perform MH surgery because it was difficult for him to lie face down for the period required for the procedure. So, we continued with monthly examinations using a spectral domain optical coherence tomography system (RS-3000 Lite, Nidek Co., Ltd., Aichi, Japan) and a nonmydriatic ultra-widefield fundus camera (Daytona, Optos Inc., Marlborough, MA, USA). After a month, retinal pigment epithelium (RPE) had developed a tear and had contracted downward, creating a large circular pigment epithelium defect. The MH progressed to retinal detachment (Fig. 2) .
After 6 months, fibrovascular proliferative tissue had spread to the subretinal space and the MH was adherent to Bruch's membrane. The MH retinal detachment disappeared but the diameter of the MH increased to 600 μm (Fig. 3) . After 11 months, there was no particular change from the previous examination. BCVA was 20/320 OS. The size of the hole remained 600 μm. One year after the initial presentation, the patient died.
Discussion/Conclusion
Some reports have described the processes of MH formation in PED. Cazabon [6] stated that in some cases of MH formation there may be a causative link with PED. Storch and Hoerauf reported that as PED increases, the retina might become stretched, and lateral extension force could create an MH [7] .
In the present case, it is difficult to confirm the possible mechanism of MH formation because the patient had hypermetropia with PVD. If the MH was formed when the PED increased, the retina should have been thinned. In the present case, there were no signs of retinal thinning at the time the first OCT was taken, and the PED is thought to be chronic due to the absence of CNV. It is unlikely that the PED significantly expanded and caused retinal thinning in the 3 months after the first OCT, so the MH was probably formed after the rupture rather than when the PED expanded. The lower height of PED is thought to be related to the beginning of RPE rupture, because the large RPE tear occurred after the PED reduction. The MH was confirmed before the contraction of the pigmented epithelium, and so there is a possibility that a different force than has been reported might be responsible for forming the MH, such as ejection of subretinal fluid to the vitreous side early after the rupture began. In fact, MH formation after spontaneous extraction of subfoveal perfluorocarbon liquid has been reported [8] .
In this case, the general mechanism of idiopathic MH formation by vitreomacular traction is not the cause because of the hypermetropia with PVD. We speculated that the MH occurred during the expansion of the PED or after the PED rupture due to a distinct unique force, such as a laterally extending force in the direction of the retina. Thereafter, the RPE shrunk to become a mass, the extension force increased, and the MH expanded.
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